Could potential associated cancer risks claw into CRISPR’s potential? The short answer from both previous and new data is that while CRISPR gene editing impacts the P53 pathway, which is involved in cancer along with having many other functions, this news is neither too surprising nor a fatal flaw, but some caution is warranted. CRISPR […]
Could Cancer Risk Claw CRISPR’s Potential? Some Balanced Perspectives Read More »
By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see
The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »
Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially reporting tons of supposed off-target CRISPR-Cas9 activity in mice, which turned out to be a “nothing
Analysis: human immunity to Cas9 bigger #CRISPR therapeutic hurdle than off-targets? Read More »
The news that CRISPR-Cas9 gene editing in its current form may not work in a substantial fraction of people due to many of us having immunity to Cas9 came as a shock to many, but if you think about it, maybe it’s not so surprising. I don’t see it as the end of the world. A (preprint) from
Keep calm & CRISPR on: perspectives on report of human Cas9 immunity Read More »
Human germline CRISPR raises major bioethical considerations, but what about technical issues? Setting aside the many ethical issue about the general idea of human modification itself, could this really work? Yes in theory it could, but there are some very tough technological challenges that could and likely would cause failures or unacceptable outcomes at many steps
7 tech hurdles to human germline CRISPR Read More »
It’s germline, heritable human CRISPR time, right? Wrong. But the particularly enthusiastic supporters of heritable human CRISPR often cite hypothetical benefits in glowing terms, but either don’t mention risks or strongly downplay them. These fans also tend to leave alternative, proven and safe technologies such as preimplantation genetic diagnosis (PGD) out of the discussion or
Countering that Pro-Heritable Human CRISPR WSJ Piece Read More »
The debate over whether the main conclusions of the Nature paper on human embryo CRISPR led by Shoukhrat Mitalipov’s lab at Oregon Health Sciences University (OHSU) are correct remains unresolved. Note that Nature just added an editorial alert just above the references section to their paper: “Updated online 02 October 2017. Editorial Note: Readers are alerted that some
Why Mitalipov’s ‘magic’ room for human embryo CRISPR may give us pause Read More »
Is President Donald Trump a fan of eugenics? He seems to believe that he comes from greatly superior genetic stock. He hasn’t said much of anything about CRISPR ‘gene editing’ technology that can readily alter the genetic code of cells of nearly any organism, including humans, but Trump has a fascination with the concept of
Wearing ‘Good Genes’: Trump & Eugenics Read More »
Science hype is one of the more troublesome issues in our field today especially at its interface with the media, and unfortunately a ‘great’ example of that came this past week in a headline from the Daily Mail on the new CRISPR of human embryos paper from Kathy Niakan’s group in the UK. Although Niakan’s
Science hype award for worst CRISPR headline Read More »
Scientist make knockout human embryos with CRISPR? Today we see a new Nature paper (Fogarty, et al.) on CRISPR “gene editing” of human embryos, this time from the UK from Kathy Niakan’s group. Niakan got UK permission about 18 months ago to CRISPR healthy human embryos so they’ve been hard at work since. Because Fredrik
1st Knockout Human Embryos Made with CRISPR: My Take on the Pub Read More »